SCHEMBL23367273

SCHEMBL23367273

CCOC(=O)/C(C=O)=N/Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.53
ALDH1A1 P00352 4/20 0.47
MAPT P10636 4/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 2/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
EPAS1 Q99814 1/20 0.47
KYAT1 Q16773 3/20 0.44
EPHX2 P34913 2/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873649 0.93 POLB (0.50) POLBALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL23367573 0.88 POLB (0.54) POLBALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL23367249 0.85 NPSR1 (0.57) POLBALDH1A1MAPTKMT2AMEN1
SCHEMBL23354894 0.85 NPSR1 (0.57) POLBALDH1A1MAPTKMT2AMEN1
SCHEMBL23354896 0.85 NPSR1 (0.57) POLBALDH1A1MAPTKMT2AMEN1
SCHEMBL23367394 0.85 KYAT1 (0.59) POLBALDH1A1MAPTKMT2ATDP1
SCHEMBL511436 0.84 POLB (0.56) POLBALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL511435 0.84 POLB (0.56) POLBALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL28039654 0.84 POLB (0.56) POLBALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL508475 0.84 POLB (0.56) POLBALDH1A1MAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058446-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
EP-3822265-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer AG (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 POLB 2132/4885ALDH1A1 2009/4885MAPT 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.